Lifeboat Foundation

https://www.hdiac.org/podcast/neuroweapons-part-1/

In part one of this two-part podcast, HDIAC analyst Mara Kiernan interviews Dr. James Giordano, a Professor in the department of Neurology and Biochemistry at Georgetown University Medical Center. The discussion begins with Dr. Giordano defining neuroweapons and explaining their applied technologies. He provides insight into the manner in which international weapons conventions govern the use neuroweapons and discusses the threats presented by neuroweapons in today’s environment. Dr. Giordano goes on to review the need for continuous monitoring, including his views regarding challenges and potential solutions for effectively understanding global developments in neuroweapon technologies.

Continue reading “HDIAC Podcast — Weaponizing Brain Science: Neuroweapons — Part 1 of 2” »

Investigators from the laboratory of Ali Shilatifard, Ph.D., the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, have discovered a new repeat gene cluster sequence that is exclusively expressed in humans and non-human primates.

The discovery, detailed in a study published in Science Advances, is a breakthrough for human genome biology and has wide-ranging implications for future research in transcriptional regulation, human evolution, and the study of repetitive DNA sequences, according to the authors.

Continue reading “New human gene cluster sequence discovered” »

The groundbreaking gene-editing technology known as Crispr, which acts like a molecular pair of scissors that can be used to cut and modify a DNA sequence, has moved rather quickly from the pages of scientific journals to the medical setting. Earlier this month, about three years after Jennifer Doudna and Emmanuelle Charpentier won the Nobel Prize in Chemistry for describing how bacteria’s immune system could be used as a tool to edit genes, regulators in the U.K. approved the first Crispr-based treatment for sickle cell disease and beta-thalassemia patients. The treatment, from Vertex Pharmaceuticals and Crispr Therapeutics, could be approved by the U.S. Food and Drug Administration early next month for sickle cell patients.

While many obstacles lie ahead for the nascent field, such as how to pay for treatments that typically cost more than $1 million, these regulatory approvals are just the start as newer gene-editing technologies such as base and prime editing make their way through human studies. In an interview, Prof. Doudna says the approval is “a turning point in medicine because it really shows how genome editing can be used as a one-and-done cure for disease.”

Gene editing is part of a broader therapeutic revolution that encompasses genetic and cellular medicine. The pills and injections we are all familiar with generally target proteins or pathways in the body to treat disease. With gene and cell therapy, we can now target the root cause of disease, sometimes curing patients.

Natural products collection reveals novel enzymes with surprising properties. Scientists have discovered two enzymes that enable bacteria to target and break up DNA. This chemical defense likely evolved to help the organism fight off germs. The chemical riches were found within the institute’s one-of-a-kind Natural Products Discovery Center collection.

Slumbering among thousands of bacterial strains in a collection of natural specimens at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, several fragile vials held something unexpected, and possibly very useful.

Writing in the journal Nature Chemical Biology, a team led by chemist Ben Shen, Ph.D., described discovery of two new enzymes, ones with uniquely useful properties that could help in the fight against human diseases including cancer. The discovery, published last week, offers potentially easier ways to study and manufacture complex natural chemicals, including those that could become medicines.

To identify potential therapeutic targets and preclinical drug candidates for the treatment of ovarian cancer, researchers led by Tan Li from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences have developed novel small molecule inhibitors of CPSF3, a key module of the cleavage and polyadenylation specificity factor (CPSF) complex that catalyzes pre-mRNA splicing and regulates transcription termination.

This work was published in Science Advances on Nov. 22.

Ovarian cancer is the deadliest gynecological cancer and is often diagnosed at a late stage. In treating ovarian cancer, surgery and systemic chemotherapy can modestly improve the survival rate, while targeted therapies with PARP inhibitors are effective in a limited number of ovarian cancer patients.

Cell toxicity and genomic instability are potential side effects from the use of CRISPR-Cas9. The gene editing tool can also cause large rearrangements of DNA through retrotransposition to theoretically trigger tumor development.

While rare, the fact that CRISPR is used to edit millions of cells for some therapies means precautionary steps are warranted given the potential increase in cancer risk. However, retrotransposition is much rarer during base editing, a more precise technique that chemically changes just one “letter” of the genetic code without causing a double-strand break in DNA.

Although MHRA decided that the benefits of Casgevy outweigh its risks, the U.K. regulator granted a one-year conditional marketing authorization of the world-first gene therapy based on the findings of two global clinical trials, noting that no significant safety concerns were identified during the trials.

University of Missouri researchers’ conceptual design of a nanomaterial could potentially pave the way for new uses of nanotechnology in medicine and science.

In a recent study, scientists at the University of Missouri developed a proof of concept for a nanocapsule — a microscopic container — capable of delivering a specific “payload” to a targeted location.

While beyond the scope of this study, the discovery has the potential to revolutionize the delivery of drugs, nutrients, and other chemicals in humans and plants. The power of the forward-thinking idea for this tiny delivery mechanism comes from its inventive structure, said Gary Baker, an associate professor in the Department of Chemistry and study co-author.

Various forms of heat pumps—refrigerators, air conditioners, heaters—are estimated to consume about 30 percent of the world’s electricity. And that number is almost certain to rise, as heat pumps play a very large role in efforts to electrify heating to reduce the use of fossil fuels.

Most existing versions of these systems rely on the compression of a class of chemicals called hydrofluorocarbons, gasses that were chosen because they have a far smaller impact on the ozone layer than earlier refrigerants. Unfortunately, they are also extremely potent greenhouse gasses, with a short-term impact several thousand times that of carbon dioxide.

Alternate technologies have been tested, but all of them have at least one major drawback in comparison to gas compression. In a paper released in today’s issue of Science, however, researchers describe progress on a form of heat pump that is built around a capacitor that changes temperature as it’s charged and discharged. Because the energy spent while charging it can be used on discharge, the system has the potential to be highly efficient.

To enhance their catalytic efficiency in degrading organic pollutants, such as RB and urea, researchers further functionalized the surface of the micromotors with laccase, the bio-catalytic counterpart, for the generation of ammonia from urea. Urea is an emerging contaminant, being a common pollutant from residential activities (urea is the main component of urine) and from different industrial processes.

The chemical component laccase accelerates the conversion of urea into ammonia upon contact with contaminated water. This ammonia can be transformed into hydrogen, which is a clean and sustainable energy source.

“This is an interesting discovery. Today, water treatment plants have trouble breaking down all the urea, which can result in eutrophication when the water is released. This is a serious problem in urban areas in particular,” says Rebeca Ferrer, a PhD student from Dr. Katherine Villa’s group at ICIQ.